Fusion Antibodies, a UK-based contract research organisation and NB Health Laboratory (NBHL), a Japan-based biotechnology company specialising in GPCR-targeting drug discovery, are entering an alliance for a research and licence agreement in the field of monoclonal antibodies.

Through the partnership, Fusion will apply its proprietary CDRTM Multiplex Humanization Platform integrated into NBHL MoGRAATMdiscovery engine which will provide high-quality humanized antibodies targeting GPCRs ready for further development to potential partners. 

“This partnership will allow Fusion to provide clients with perfect antibody candidates and close collaborations. Clients will be able to get access to rapid discovery and development of new antibodies through NBHL MoGRAATM discovery engine. (MoGRAATM, which stands for “Modification of G-protein coupled Receptor Activation with monoclonal Antibody, is a new bio therapeutic concept for GPCR targeted drug discovery)”, said Dr Paul Kerr, Managing Director, Fusion Antibodies.

“Developing of functional antibody targeting GPCRs is still challenging.  Especially, the humanization is one of critical steps. Through the partnership, Fusion’sCDRTM Multiplex Humanization Platform is involved in NBHL MoGRAATM discovery engine to accelerate the generation of therapeutic antibody targeting GPCRs.  We believe that this alliance will bring about benefit to both of companies “, said Dr Kiyoshi Takayama, President, NBHL.

 About NBHL and its discovery engine.

NB Health Laboratory is a biotechnology company dedicated to discovering, developing and commercializing innovative medicines to treat respiratory diseases, chronic inflammation and central nervous system disorders. NBHL has expertise in the generation of functional antibodies targeting G protein-coupled receptors (GPCRs) and is pioneering a new field in GPCR-targeting drug discovery to benefit human health.

NBHL has established a technology platform for the generation of functional mAbs targeting GPCRs to pioneer a new field in GPCR-targeted drug discovery, in collaboration with universities and other partners in Japan. NBHL has used the technology platform to discover promising mAbs targeting GPCRs for the treatment of respiratory diseases and chronic inflammation, which is being progressed towards clinical development.

For more information, please visit http://www.nbhl.co.jp/

About Fusion Antibodies and its humanization platform

Fusion Antibodies is a Contract Research Organisation (CRO) established in 2001 as a spin-out from Queen’s University Belfast and located about 6 miles outside Belfast city centre. With many years of experience in the medical research industry, including two of its own antibodiesin clinical and pre-clinical trials.

Fusion Antibodies have developed a next generation in silico platform for rapid, reliable and robust antibody humanization. The primary function of our software is to perform the initial screen of 100,000+ human antibody sequences and display the top matches (based on homology). This tool allows the screening of large databases and is critical to selection of an appropriate human recipient antibody.

Fusion Antibodies and BizCom Japan, a privately-held Japan-based trading and consulting company, continue to strengthen ties with Fusion’s Director Paul Kerr attending BioJapan 2016 with BizCom Japan’s Director Hiroyasu Nakatani.

BizCom Japan Inc. has been engaged in sales and marketing of research reagents, services and equipment to the life science research market in Japan and consulting for innovative biotech companies in Japan as well as other countries, and has extensive experience in establishing various types of alliances with Japanese companies and public institutions. BizCom Japan, Inc. use this experience and its sales and marketing expertise to exclusively market services and products of Fusion Antibodies in Japan.

To find out more information about BizCom Japan, please visit http://www.bizcomjapan.com 

To find out more information about BioJapan 2016, please visit http://www.ics-expo.jp/biojapan 

Fusion Antibodies has the privilege of showcasing their expertise and sponsoring the Antibody Engineering & Therapeutics conference in San Diego this December.

The Antibody Engineering & Therapeutics conference which began over 25 year ago is an exhibition of Antibody Science, Technology and Networking. The conference will feature over 225 speakers on a range of topics as Preclinical and Clinical Development, Engineering Antibodies for T-Cell Therapy and the Interface between Passive & Active Immunotherapy. The conference also gives the opportunity to network with over 800+ industry and academic researchers, engineers and executives.

The Fusion team (Dr Paul Kerr and Dr Richard Buick) will be attending the conference from December 11th to the 15th and showcasing their expertise.

“Looking forward to meeting fellow scientists in the antibody drug discovery fields and showcase Fusion’s CDRx humanization platform and our expertise in related services from antibody drug discovery to clinical supply” Paul Kerr. Managing Director at Fusion Antibodies

Fusion Antibodies managing director Paul Kerr recently met with PharmaTV News’ Adrian Dawkes to dissuss our Antibody Humanziation platform.

Fusion Antibodies managing director Paul Kerr recently met with PharmaTV News‘ Adrian Dawkes to dissuss our Antibody Humanziation platform. Check out the video interview above or the video transcript below.

Video Transcript

Adrian Dawkes: Hello and welcome to Pharma Television News review, here at the Anglonordic life science conference 2016 in London. On the show today I have Paul Kerr, the managing director of Fusion Antibodies. Paul, welcome.

Paul Kerr: Ok, thanks for having me Adrian

Adrian: Pleasure. Fusion Antibodies – It’s a name that’s been around a little while but I think your company has been through a couple of changes. Perhaps you could start at the beginning and give us the story.

Paul: Well I’ll give you the short version of the story or it would be a very long interview. Basically we were founded as a spin off from Queen’s University in 2000. And when we started we were primarily a therapeutic drug discovery company, in antibody drug development, in oncology. So for the next ten years we perused developing a number of targets in the oncology space. But when I took over as managing director, we really pivoted over to being a full service CRO company in the antibody humanization and cell line development space and putting some of our R and D targets secondary and running them on the more virtual model.

Adrian: And what was the driver for that? Because normally people kind of flip the other way. They start off doing a service business and thinking actually I could develop some drugs, why don’t I do that because the riches are beyond imagination. But you went the other way. Was it financial? What was the driver for this?

Paul: Financial. By the time one of our lead targets, Cathepsin S was ready to go towards the clinic, we got hit by the tsunami of the credit crunch of 2008 and 2009. And, really we had to re evaluate exactly how we were going to move forward and keep the whole company moving forward so we had to basically flip everything right over. So we reached a really critical point where we needed a substantial injection of cash to go to the clinic and cGMP production, and it was just at the wrong time.

Adrian: You did the smart thing. Survival mode, gathered some business and it’s grown from there?

Paul: Absolutely. Well, prior to being first and foremost being a drug discovery company and drug development company, we also did a little bit of CRO work, just through the contacts we had. It wasn’t really the main thing. The main thing was the drug discovery, but, as you said, as you go forward with the drug discovery, it is a huge investment. And so, really, to survive we needed cash, we needed to go back to what we’re really good at, engineering antibodies, sequencing antibodies and humanization of antibodies. So moving forward we developed a next generation CDRx grafting platform, an in silico computer based algorithm, that combined looking at the CDR definitions of Kabat, Chothia, IMGT. To make a more rapid robust method of humanization and really we developed that and went round in 2012, 2013 to sort of promote that to clients around the world. So that has been a fantastic success and led us to a path of profitability.

Adrian: Well that’s great to hear that the model you’ve adopted has made a successful business out of that. And the business is founded in antibody engineering, as you’ve just said CDR grafting, it’s an area I’m familiar with from another life when I worked for a company that did the same thing back in the 80’s. So that’s a technology that’s been around for a while. But you mentioned some words there, in silico, where we’ve done a special algorithm. What are you guys doing different to differentiate? Becuase there are a lot of companies out there doing antibody engineering of some sorts.

Paul: True. Well what we went back to focus on, we know that a lot of people doing antibody engineering are trying to humanize or make humanized variants. To get around the main CDR grafting patents they looked at other methods of achieving that and getting a little bit of IP around that but we felt that maintaining the conformational integrity of the antibody was the highest priority for manufacturability. So we wanted to not only make the best humanized candidates we could in terms of conformational integrity but also look at the manufacturability from the get go in terms of expression and cell line development. So when we made the humanized variants we would make a matrix and screen those in small amounts to ensure, of course, that we’ve maintained the integrity of the antibody in terms of its binding, characteristics to the parental and then also we wanted to select ones that had the capability of going all the way to commercialisation. So really planning for success at the very outset.

Adrian: So you’ve got some special methodology where you do what you do, but you can pin point and say, actually that’s the antibody that’s going to make it all the way through to scale up and manufacturing into the clinic and become potentially if it’s efficacious and safe, a therapeutic product.

Paul: Absolutely, and what we’re concentrating on is our expertise in the antibody humanization. Designing that, and the cell line development, so providing the tools to allow our clients from large pharma right down to mid tech biotech’s to spin out companies. To provide them the necessary materials and materials at the right point and the right time in the right format so they can do the actual scientific testing. The reason why the antibody was selected in the first instance. And moving forward we’ve a network of high quality service providers from drug discovery through Mab Discovery in Munich to Protogen for analytics, Biaffin for biacore analysis and we also have a partner for cGMP production and we use their cell lines, Celonic in Basil in Switzerland. And in the oncology side for cell line development and in vitro, in vivo trials we have a partner in Paris called Early Stage Drug Discovery.

Adrian: Ok but there’s no focus in the service business other than it’s antibodies, you’ll do it across therapeutic areas, whatever people come to you and say make me an antibody you can do it.

Paul: Absolutely, and whatever that antibody is we will engineer it to the best possible humanized variant.

Adrian: Do they have to give you a murine antibody as a starting point? Where’s the start?

Paul: Starting point is a sequence, either murine, we’ve done murine, we’ve optimised our CDRx algorithm murine, mouse, rat, rabbit also, we’ve definitely been specialising a lot in rabbit because we also see that they do produce higher affinity antibodies and we’ve also been involved in a few llama projects and even humanizing a chicken. So in the last 4 or 5 years we’ve done about 55 humanization projects from Japan, Europe, and US.

Adrian: And presumably you’ve been doing that a while. Are some of these in the clinic already?

Paul: Well we know that there’s 4 of the first, let’s say 20 or so antibody projects we’ve been involved in 3 or 4 years ago, they are now starting to enter the clinical trials this year and early next year

Adrian: And are they behaving as you predicted?

Paul: Well because we we’re fee-for-service, some of them are large pharma based companies and we don’t actually know. And it’s only through meeting people and they are telling us, “oh, that’s progressing”. We don’t even know what the target is for them or anything in some of the cases. In some of the smaller companies we would have more feedback so from this it’s been excellent.

Adrian: No news is good news in that respect.

Paul: Well, I think as long as it’s going forward into the clinic, we’re delighted.

Adrian: How do you line up against the HuCAL mouse or other technologies that give you totally human antibodies rather than the CDR grafted of which there are, drawing on my ancient history, you still get some anti-human responses around the CDRs maybe towards the variable regions where you have to make slight adjustments. Do you still see that or is the technology moved on?

Paul: We think the technology has moved on. We can do further enhanced polishing steps. When we do the humanization we do identify, we do an in silico epitope screen and we identify T cell epitiopes potentially inside the CDRs. But primarily in our first matrix of humanized variants we tend to highlight them but leave them alone because, first and foremost those T cell epitopes may be critical for the formation of why that antibody is unique and why it was selected in the first place. So we first do the humanization and in consultation with the clients we say “we can make additional substitutes here to remove any possible immunogenicity”. So it’s a second stage polishing step that we would offer.

Adrian: So what’s the business model? Do you risk share? Do you have reach-throughs to the drugs? Or is it just pay and play and go away?
Paul: When we started it was just basically pay and play and on they go but now as we have matured and got a lot more confidence in the technologies that we have and in what we are putting into the drug discovery process and development for the clients we have now moved towards a success fee based payments. Every deal is negotiable so some people want to pay the money and it’s theirs but more lately we have been doing more risk share reward, success payments. It’s still royalty free but it’s basically a reduced upfront payment and then a success payment when it hits the clinic or different milestones.

Adrian: Ok. And are you generating IP for your partners or do they rely upon IP that you hold? They have to licence.

Paul: No when we do the service the partner has the full rights to use the technology. There’s no additional contract negotiations required. So it really is fee for service with just straight forward one off success payments. Very simple.  So what we’re trying to do is encourage more and more people who are using the mouse or other, rabbit, antibodies to allow them to come earlier to get them humanized and get the drug candidate and work on that as soon as possible.

Adrian: And you’ve still got a few things from the old days in the drug discovery days going on?

Paul: Absolutely yea, one of our main antibody target was fsn0503 an anti cathepsin S protease inhibitor and we’ve partnered up with a company in Australia called Clarity Pharmaceuticals who do a fantastic job in adding their technology in terms of imaging to find out exactly where it goes and also use their radio nucleotides in terms of imaging and as a therapeutic agent to add extra bang and killing power to the molecule that we’ve created.

Adrian: Well Paul it’s great to hear that you’ve made a success out of an antibody engineering company and generating good business and excellent products that hopefully make their way to the clinic. Thanks for joining us today.

Paul: Ok, Thank you Adrian.

Fusion Antibodies ltd has the great honour and privilege to welcome the 20th Human Antibodies & Hybridoma conference to our home city of Belfast this November.

It continues to be a great time of hope and optimism in the knowledge of the immune system since the first report of the immortalisation of monoclonal antibodies by Kolner & Milstein in 1975. By my last count there were 49 antibody approved drugs to date with 15 approvals since 2015.

In 2015, twenty approvals (39%) went to biological drugs, up from 35% in 2014 and 22% in 2013, which confirms the growing importance of biopharmaceuticals in the industry pipeline. Twenty drugs (39%) featured ‘first-in-class’ modes of action—about the same as in 2014 (39%) and 2013 (37%).

From the beginning of the HAH conference series in April 1990 in Orlando Florida, the event has been all over the world. Over the past 26 years the Human Antibodies and Hybridomas conference has tracked the advances in the knowledge of antibody engineering and humanization, expression of industrial quantities of antibodies and both followed and met the challenges of developing new drugs for many different disease indications. Scientists continue to improve methodologies in screening and production of antibodies to an ever increasing range of disease indications, with the precision we all dared to hope many years ago.

I welcome to Belfast all the scientists, companies and entrepreneurs from across the globe to share their talents, knowledge & experience to find ways of overcoming the barriers and the challenges we face to make the next generation of medicines. The journey continues as we look to improve and share the knowledge and advances.

–          Paul Kerr, Managing Director, Fusion Antibodies

Notable Northern Irish Scientists

  • Frank Pantridge – Inventor of the portable defibrillator and known as the ‘Father of Emergency Medicine’. – Hillsborough, County Down, Northern Ireland
  • Lord Kelvin – . Pioneered studies in thermodynamics and contributed to the development of the refrigeration. – Belfast, County Antrim, Northern Ireland
  • Jocelyn Bell Burnell DBE FRS FRSE FRAS (born 15 July 1943) is a Northern Irish astrophysicist. As a postgraduate student, she discovered the first radio pulsars 
  • Hans Sloane – Creator of Chocolate Milk. During a trip to Jamaica, Hans discovered cocoa. Finding it nauseating to drink mixed with water, he brought it home and mixed it with milk. – Killyleagh, Co Down, Northern Ireland
  • Harry Ferguson – Inventor and developer of the modern agriculture tractor. – Growell, Co Down, Northern Ireland
  • David Bates – Mathematician and Physicist. His contributions to science include seminal works on atmosphere physics, molecular physics and the chemistry of interstellar clouds. – Omagh, County Tyrone, Northern Ireland
  • John Stewart Bell – Physicist. Originator of Bell’s Theorem, an important theorem in quantum physics regarding hidden variables theories. – Belfast, County Antrim, Northern Ireland
  •  William C. Campbell  Biologist – 2015 Noble prize winner  “for discoveries concerning a novel therapy against infections caused by roundworm parasites” Ramelton, Co Donegal
  •  Ernest Walton Physicist – 1951 Noble prize winner ‘splitting the atom’ Methodist college, Belfast

Fusion Antibodies are happy to announce we have entered into a partnership with Swiss contract manufacturing organisation Celonic AG to collaborate on the development of high yield stable cell lines.

The deal will allow clients of Fusion Antibodies a direct & efficient supply path to clinical trial material by taking advantage of the scale-up and development capabilities of Celonic. Fusion Antibodies and Switzerland based CDMO Celonic, a leading provider of services for the development and cGMP production of biopharmaceuticals, have today announced a partnership to offer Celonic’s CHOvolution cell line development technology to our clients.

The collaboration will allow Fusion Antibodies’ clients access to the Celonic stable and high titre (>7g/l) platform at an earlier stage and at a competitive cost as the materials are non-GMP and suitable for pre-clinical development. Once a client has completed the applicable preclinical studies, the cell line can be easily transferred from Fusion to Celonic for further development & supply of clinical ready GMP material.

Our Paul Kerr, Managing Director at Fusion Antibodies commented:“We are delighted to deepen our relationship with Celonic. This partnership allows us to offer our clients a ‘one stop shop’ supply of antibody drug candidate materials from discovery right through to clinical development. Clients do not need to change to a production cell line after their R&D thereby saving time, money and adding project safety as preclinical and clinical results will be easier to compare”

Konstantin Matentzoglu added: “I am excited about this truly enabling partnership, which goes beyond a loose out-licensing/co-marketing deal. Celonic and Fusion Antibodies engage together and will offer highly aligned services to provide a safe and efficient development approach to clients worldwide.”

To find out more about Fusion Antibodies, visit our ‘About Us’ page at http://fusionantibodies.com/who-we-are/about-fusion-antibodies.

About Celonic

Celonic AG is privately owned CDMO based in Basel, Switzerland providing comprehensive GMP development and manufacturing services for New Biological Entities (NBEs) and Biosimilars worldwide. Applying empathy, efficiency and excellence, Celonic goes one step beyond expectations in all business aspects in order to help its clients attain their goals better, more efficiently and reliably.

Celonic’s services include the development of cell lines, production processes as well as the GMP and non-GMP manufacturing of biopharmaceutical drug substances. In addition, Celonic licenses its proprietary CHOvolution cell line technology to clients, drug developer and service provider.

Visit their website http://www.celonic.com/ to learn more.

Fusion Antibodies are looking to hire a Business Development Manager to join their team based in Belfast, UK.

Are you looking to join an innovative manufacturer of a range of high quality antibodies for drug development and diagnostics? Do you want to benefit from genuine career prospects with a clear route to progress to a management level role? Due to a period of exponential growth, Fusion Antibodies currently have an opportunity for a Business Development Manager to join their team based in Belfast. 

Basic Salary Circa: £24,000 – £40,000 (DOE) + Bonus + Share options + Pension

The Duties of the Business Development Manager:

  • Maintain and develop relationships with existing customers to grow long-term effective business relationships
  • Pro-actively search and connect with new prospects
  • Visit key customers and prospects
  • Maintain relationships with and visit European / US Clients
  • Report on sales and business development targets
  • Attend European & Global exhibitions relevant to the business
  • From your experiences in the field, provide feedback to Marketing and Product Development team on customer and competitor activities
  • Cohesively partner technical sales support colleagues to deliver a consultative sales approach to maximise impact and results
  • Promote and secure sales opportunities, industry networking and strong customer relationship management

The Profile of the Business Development Manager:

  • Must be educated to Degree or Masters level in a Life Science discipline
  • Demonstrable experience of international client facing and sales
  • Candidates must be prepared to travel in Europe and internationally on a regular basis (around two weeks per month)
  • Proven sales experience selling product or services to pharmaceutical, biotechnology or research sectors.
  • Independent, driven and able to work on own initiative
  • A highly organised individual capable of managing large client portfolios
  • Experience with face-to-face and/or telephone sales
  • Full UK driving licence
  • Must be based within commutable distance to Belfast


  • Territory experience preferably across Europe, USA
  • An intermediate/advanced level of ability with Microsoft Word
  • Experience with a digital CRM system

To apply:

Please send a CV and Covering letter to jobs@fusionantibodies.com

Fusion Antibodies are pleased to announce a second collaboration with Aerpio Therapeutics to apply our CDRx Antibody Humanization platform to Aerpio’s Mouse Monoclonal Antibody.

Fusion Antibodies Ltd are excited to announce our second collaboration with Aerpio Therapeutics, of Cincinnati, Ohio. Aerpio are biopharmaceutical company focused on advancing first-in-class treatments for the eye. Following the success of the companies’ first antibody development program, completed in 2015, Fusion Antibodies has now initiated a second antibody humanization program with Aerpio. 

The partnership caps another record-breaking year for Fusion Antibodies’ Humanization service. In the past 12 months more than 30 projects have been completed. Paul Kerr, Managing Director of Fusion Antibodies – “We are excited to have the opportunity to extend our collaboration with the team at Aerpio and look forward to delivering a panel of quality humanized antibodies using our CDRx platform. The work Aerpio Therapeutics is doing on diabetic eye disease is cutting edge and very exciting to be part of.” Kevin Peters, Aerpio Therapeutics’ Chief Scientific Officer, stated, “We’re pleased to begin our second antibody humanization program with Fusion Antibodies. The first project went very well and yielded multiple humanized clinical candidates. The success of the first program was a tribute to the experience and knowledge of the Fusion Antibodies team and to the collaborative nature of the Fusion culture.”

About Aerpio Therapeutics

Aerpio Therapeutics, Inc. is a clinical‐stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of vascular disorders with an emphasis on diseases of the eye. Aerpio is a leader in the development of therapeutics based on Tie2 activation and the stabilization of hypoxia-inducible factor 1α (HIF‐1α). The Company’s lead program, AKB‐9778, is a first‐in‐class small molecule stabilizer of the Tie2 pathway and is in clinical development for diabetic eye disease. More information is available at www.aerpio.com.

Fusion Antibodies Ltd are pleased to announce the in-licensing of the anti-AM2R monoclonal antibody from Medella Therapeutics, to use our CDRx™ humanization technology to develop it as a novel 1st in class therapy for serious cancers with an unmet clinical need.

AM2R is one of two distinct heterodimeric cell-surface receptors for the hormone Adrenomedullin (AM), which is responsible for several important functions including control of blood pressure, as well as playing a key role in the growth and spread of many cancer types.  AM’s physiological role is mediated primarily through the heterodimer AM1R, containing the protein RAMP2, but it is through selective targeting of AM2R, containing the protein RAMP3, that cancer growth and spread can be inhibited. RAMPs are a small family of transmembrane proteins that associate with a group of non-specific cell-surface receptors, to coordinate a range of different physiological responses.

Paul Kerr, Managing Director of Fusion Antibodies: “We have worked with Medella Therapeutic’s team as a CRO and the opportunity to increase our involvement with this exciting antibody is something were we can add significant value through our expertise in humanization and antibody drug development.”

Professor Tim Skerry, CSO of Medella Therapeutics and Head of the Department of Oncology and Metabolism at the University of Sheffield said,” Thanks to the support of IP Group plc, Medella Therapeutics have progressed the idea of inhibition of AM2R with a monoclonal antibody through early preclinical development to a stage where humanization of the antibody is the next step towards regulatory approval and clinical trials.  Having worked with the Fusion Antibodies team in the past, we are excited to partner with them to take the project forward with their cutting-edge technologies and services.  We are optimistic that the work will lead to a robust clinical candidate.  AM2R is becoming recognised as an important target in oncology, because of its widespread expression in tumour cells and involvement in metastasis, yet low levels of expression in normal host tissues.  We hope that a humanized anti-AM2R antibody will offer targeted treatment for cancers with currently unmet clinical need.”

About Medella Therapeutics

Based on the leading research of Prof Tim Skerry and Dr Gareth Richards, Medella Therapeutics Limited is a spin-out company from the University of Sheffield, focused on the discovery and development of novel drugs that interfere with the cell signalling activities of Receptor Activity Modifying Proteins (RAMPs).  RAMPs are exciting targets implicated in a range of diseases including bone disease, cancer, cardiovascular disease, inflammation, neurological function and obesity.

About Fusion Antibodies

We are a UK based life science company with innovative technologies and world-class expert services for therapeutic antibody drug discovery & development, are specialists in the production of High Quality Humanized Monoclonal Antibodies and Antibody Cell Line Development Projects.  With over 15 years of experience in the medical research industry, including multiple Antibodies in clinical and pre-clinical trials, Fusion Antibodies have extensive experience in accelerating therapeutic drug research towards the clinic.

Fusion Antibodies has the knowledge and expertise to build and deliver a bespoke package of the services you need to achieve outstanding results.  We provide Royalty-Free Antibody Humanization of Monoclonal Antibodies and using our next generation in-silico CDRx™ technology, have modernized the traditional CDR grafting technique.  Humanized monoclonal antibodies are an essential step in the progression of therapeutic drugs to the clinic and the in-house expertise at Fusion Antibodies ensures its success.

Fusion Antibodies, a UK-based contract research organisation and MAB Discovery, a unique antibody discovery company, have announced their intention to enter into a research and licence agreement in the field of monoclonal antibodies.

Within the scope of this collaboration, Fusion Antibodies will apply our proprietary CDRx™ Multiplex humanization platform to generate therapeutic antibodies, selected and produced by MAB Discovery, who will provide high-quality humanized antibodies ready for further development to potential partners.

“Through this collaboration we are able to create synergies and provide clients with perfect antibody candidates. They will get access to rapid discovery and development of new antibodies through MAB Discovery’s unique immunization and B cell cloning technology. MAB Discovery has developed a rabbit-based platform that produces monoclonal antibodies with unprecedented epitope coverage and potency,” said Dr Paul Kerr, Managing Director, Fusion Antibodies.

“We are very pleased to be working with Fusion Antibodies, a well-respected antibody engineering firm with strong expertise in humanization,” said Dr. Stephan Fischer, Chief Executive Officer of MAB Discovery. “The planned collaboration will enable us to provide our customers added value by offering high-quality humanized antibodies that are ready to be validated and brought into development. We also expect that combining our technologies will reduce the time from target to clinical candidate.”

About MAB Discovery and its technology platform 
MAB Discovery is focused on creating a vast repertoire of high quality monoclonal antibodies in terms of potency and epitope coverage for its clients, who include biotech and pharmaceutical companies such as Sanofi, GenMab A/S, Synthon Biopharmaceuticals and others.

MAB Discovery’s proprietary technology utilizes the natural antibody maturation process following immunization. Rather than relying on conventional single hit optimization techniques of a few selected antibodies, the MAB Discovery approach creates a diverse collection of many hundreds of high affinity antibodies. The company uses state-of-the-art automation to select and clone B cells expressing matured antibodies deriving from the immunized animal’s entire repertoire to a given immunogen. Using this sophisticated high throughput approach enables MAB Discovery to select antibodies for functionality at an early stage and not just by simple binding. The MAB Discovery team represents a group of scientists out of Roche Biologicals R&D with extensive experience in developing biologically based therapeutics. For more information, please visit http://www.mabdiscovery.com.


Fusion Antibodies 
Dr. Paul Kerr, Managing Director 
+44(0) 2890 432800 

MAB Discovery: 
Dr. Stephan Fischer, CEO 
+49 89 990 178-0